IQWiG reports benefits of Halaven in Breast Cancer are proven - Eisai

The German Institute for Quality and Efficiency in Health Care (IQWiG) has published a report which concludes that an additional benefit of Halaven (eribulin), from Eisai, versus certain comparator therapies for the treatment of women with locally advanced or metastatic Breast Cancer who have progressed after at least one chemotherapeutic regimen for advanced disease has been proven. The reassessment for eribulin is based on clinical evidence derived from two global Phase III trials; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Treatment of Physician's Choice Versus E7389) (Study 305) and Study 301. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments. The G-BA is expected to publish its final decision after due consideration of the IQWiG report, written statements and an oral hearing at the end of January 2015.